AI Summary
The article discusses the potential connection between immune checkpoint inhibitors (ICIs) and osteoporotic fractures, which are not currently recognized as immune-related adverse events (irAEs). While ICI-associated arthritis is well-documented, the direct effects of ICIs on bone in cancer patients are poorly understood. Emerging evidence suggests ICIs may impact bone turnover, leading to osteoporosis and fragility fractures. This highlights the need for further research on the skeletal effects of ICIs and their potential adverse events.
The widespread use of immune checkpoint inhibitors (ICIs) in clinical practice has broadened our understanding of their immune-related adverse events (irAEs). IrAEs, including musculoskeletal adverse events, remain a significant concern. While ICI-associated arthritis is a well-documented musculoskeletal side effect of ICI therapy, the direct effects of ICIs on bone in patients with cancer are poorly understood. There is emerging evidence to support the hypothesis that ICIs adversely impact bone turnover and can lead to osteoporosis and fragility fractures, which are not currently recognized as irAEs.